Bispecific Antibodies in the Treatment of Multiple Myeloma: Expert and Patient Perspectives

Ajai Chari, MD, provides a quick overview of multiple myeloma and patient Anne-Marie Jacob shares the story of her diagnosis.

Nurse Practitioner Kiah Purcell and Registered Nurse Annel Urena explain their role in the diagnosis and education of a patient with multiple myeloma.

Anne-Marie Jacob describes her early treatment regimen for multiple myeloma and her experience with clinical trial enrollment.

Dr Ajai Chari explains the mechanism of action of BCMA-targeting bispecifics and the role of teclistamab in multiple myeloma treatment.

A review of the process of giving a patient a dose of teclistamab from start to finish.

A review of the process of “step-up” doses in teclistamab therapy for multiple myeloma and their use.

Nurse Practitioner Kiah Purcell explains how she discusses supportive care agents with patients receiving a BCMA-targeting bispecific for multiple myeloma in case a patient experiences cytokine release syndrome.

Anne-Marie Jacob shares advice for patients with multiple myeloma receiving teclistamab who are recommended for hospital admission for CRS risk.

The panel discusses the importance of discussing COVID with patients with multiple myeloma and stressing the need to get vaccinated.

The panel continues their discussion on infection risk with a look at the immunosuppressive effects of BCMA-targeting bispecifics.

A look at the quality of life of patients with multiple myeloma who received CAR T-cell therapy.

The panel shares closing advice for patients with multiple myeloma receiving teclistamab, and community providers and nurse practitioners administering teclistamab to patients.

Anne-Marie Jacob, a patient with multiple myeloma, discusses the treatment of multiple myeloma with bispecifics alongside a panel of experts.